PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: The Scott Partnership

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Novozymes Showcases Leading Biopharmaceutical Solutions At BioProcess International 2010 - Novozymes Biopharma will be showcasing its innovative portfolio of biopharmaceutical technologies and solutions at the 2010 BioProcess International Conference and Exhibition
Novozymes Showcases Leading Biopharmaceutical Solutions At BioProcess International 2010

 

NewswireToday - /newswire/ - Holmes Chapel, Cheshire, United Kingdom, 2010/09/02 - Novozymes Biopharma will be showcasing its innovative portfolio of biopharmaceutical technologies and solutions at the 2010 BioProcess International Conference and Exhibition.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Novozymes Biopharma, part of Novozymes A/S, world leader in bioinnovation, will be showcasing its innovative portfolio of biopharmaceutical technologies and solutions at booth #507 and #509 at the 2010 BioProcess International Conference and Exhibition, 20-24 September at Rhode Island Convention Center, Providence, RI, USA.

The annual conference and exhibition aims to accelerate and improve biopharmaceutical processes and product development, attracting key personnel from across the bioprocessing industry. At this year’s event Novozymes’ booth will feature the company’s range of regulatory compliant, recombinant and animal-free products and technologies. These innovative solutions offer improved manufacturing efficiency, increased safety and result in superior final products.

During the five day conference, Novozymes will be presenting two technical posters entitled “Albumin: A robust pharmaceutical excipient in the stabilization of protein therapeutics’ and “Application of animal-free recombinant bioactive protein supplements to improve the performance of cell-based viral vaccine production”. In addition the company will deliver a presentation on the “Impact of recombinant albumin on the stability of a malarial antigen vaccine”.

Novozymes will also be hosting a workshop on “Improving biomanufacturing efficiency through recombinant solutions”. Company experts will discuss how the introduction of innovative technologies and products and ongoing collaborative dialog with the biomanufacturing industry are driving efficiency improvements across the biopharmaceutical lifecycle.

The company will also be discussing its recent announcement of a 10-year extension to its joint agreement with SAFC®, a member of the Sigma-Aldrich® Group. The renewal sees SAFC retain exclusive marketing and distribution rights for Novozymes’ LONG ®R³IGF-I (LONG®R3) growth factor.

To learn more about the company’s biopharmaceutical technologies and solutions, please visit Novozymes at booth #507 and #509 at the 2010 BioProcess International Conference and Exhibition.

About Novozymes
Novozymes (novozymes.com) is the world leader in bioinnovation. Together with customers across a broad array of industries we create tomorrow’s industrial biosolutions, improving our customers' business and the use of our planet's resources.

With over 700 products used in 130 countries, Novozymes’ bioinnovations improve industrial performance and safeguard the world’s resources by offering superior and sustainable solutions for tomorrow’s ever-changing marketplace.

Novozymes’ natural solutions enhance and promote everything from removing trans fats in cooking, to advancing biofuels to power the world tomorrow. Our never-ending exploration of nature’s potential is evidenced by over 6,000 patents, showing what is possible when nature and technology join forces.

Our 5,000+ employees working in research, production and sales around the world are committed to shaping business today and our world tomorrow.

Contacts:
Novozymes Biopharma
Sally Vernon, Customer Communications Manager
E: SYKE[.]novozymes.com.

Corporate Contacts:
Press and media:
Johan Melchior , T: +45 4446 0690, M: +45 3077 0690

René Tronborg
T: +45 4446 2274, M: +45 3077 2274

Paige Donnelly (USA)
T: +1 919 494 3209, M: +1 919 218 4501

Investor relations:
Tobias Bjørklund, T: +45 4446 8682, M: +45 3077 8682

Thomas Bomhoff (USA)
T: +1 919 494 3483, M: +1 919 649 2565

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: The Scott Partnership

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Novozymes Showcases Leading Biopharmaceutical Solutions At BioProcess International 2010

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Scottpr.com 
+44 1477 539539
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any The Scott Partnership securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From The Scott Partnership / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)